|
Variable
|
Categorization
|
IHC
|
Realtime PCR
|
|---|
| | |
n1
|
%
|
n1
|
%
|
|---|
|
Clinicopathological factor:
| | | | |
|
Age at diagnosis
| | | | |
|
Median, range (years)
|
57.5 (25–82)
|
57.5 (28–85)
|
| |
≤ 50 years
|
54
|
29.2
|
10
|
27.8
|
| |
> 50 years
|
128
|
69.2
|
26
|
72.2
|
| |
unknown
|
3
|
1.6
|
0
|
0
|
|
Tumor stage2
| | | | | |
| |
pT1
|
46
|
24.9
|
15
|
41.7
|
| |
pT2
|
92
|
49.7
|
16
|
44.4
|
| |
pT3
|
13
|
7.0
|
0
|
0
|
| |
pT4
|
30
|
16.2
|
4
|
11.1
|
| |
pTx3
|
4
|
2.2
|
1
|
2.8
|
|
Lymph node status2
| | | | |
| |
pN0
|
71
|
38.4
|
19
|
52.8
|
| |
pN1–3
|
104
|
56.2
|
15
|
41.7
|
| |
pNx3
|
10
|
5.4
|
2
|
5.6
|
|
Grading
| | | | | |
| |
G1/G2
|
100
|
54.1
|
19
|
52.8
|
| |
G3
|
80
|
43.2
|
15
|
41.7
|
| |
Gx3
|
5
|
2.7
|
2
|
5.6
|
|
Histological type
| | | | | |
| |
ductal
|
145
|
78.4
|
34
|
94.4
|
| |
lobular
|
13
|
7.0
|
1
|
2.8
|
| |
other
|
19
|
10.3
|
1
|
2.8
|
| |
unknown
|
8
|
4.3
|
0
|
0
|
|
Immunohistochemistry (IHC):
| | | | |
|
Estrogen receptor status
| | | | |
| |
negative (IRS4 0–2)
|
49
|
26.5
|
11
|
30.6
|
| |
positive (IRS 3–12)
|
97
|
52.4
|
21
|
58.3
|
| |
unknown
|
39
|
21.1
|
4
|
11.1
|
|
Progesterone receptor status
| | | | |
| |
negative (IRS4 0–2)
|
107
|
57.8
|
12
|
33.3
|
| |
positive (IRS 3–12)
|
49
|
26.5
|
20
|
55.6
|
| |
unknown
|
29
|
15.7
|
4
|
11.1
|
|
HER2 expression status
| | | | | |
| |
negative (0–1+)
|
120
|
64.9
|
6
|
16.7
|
| |
positive (2+-3+)
|
38
|
20.5
|
5
|
13.9
|
| |
unknown
|
27
|
14.6
|
25
|
69.4
|
- Characteristics of primary breast carcinomas used for ITIH2 immunohistochemistry (n = 185) and real-time PCR (n = 36) analysis.
-
1Only female patients with primary invasive breast cancer were included. 2According to UICC: TNM Classification of Malignant Tumours (2002) [65]. 3x = status unknown. 4IRS = Immunoreactivity score according to Remmele and Stegner (1987) [47].
